Caisse Des Depots ET Consignations Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Caisse Des Depots ET Consignations purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 304,689 shares of the biopharmaceutical company's stock, valued at approximately $8,083,000.

Other institutional investors have also added to or reduced their stakes in the company. United Bank grew its position in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after buying an additional 1,277 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Pfizer by 67.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock valued at $428,000 after acquiring an additional 5,959 shares in the last quarter. Loomis Sayles & Co. L P increased its position in Pfizer by 7.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 8,450 shares of the biopharmaceutical company's stock valued at $245,000 after purchasing an additional 577 shares during the period. Dai ichi Life Insurance Company Ltd raised its holdings in Pfizer by 32.6% in the 3rd quarter. Dai ichi Life Insurance Company Ltd now owns 243,824 shares of the biopharmaceutical company's stock worth $7,056,000 after purchasing an additional 60,000 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Pfizer by 3.1% in the 3rd quarter. FMR LLC now owns 14,478,489 shares of the biopharmaceutical company's stock worth $419,007,000 after purchasing an additional 435,311 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Price Performance

PFE stock traded up $0.19 during mid-day trading on Friday, hitting $25.20. The company had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The company has a market capitalization of $142.93 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a 50-day moving average price of $26.06 and a 200 day moving average price of $26.92. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Finally, Bank of America restated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.